一种新的肺炎疫苗在50岁以上的成年人中显示出强大的保护性, 超过目前11个新株的选择. A new pneumonia vaccine shows strong protection in adults 50+, outperforming current options for 11 new strains.

瓦克西特对VAX-31进行的一期1/ 2试验,该疫苗为31肺炎球菌疫苗,在50岁及以上的成年人中显示出强烈的免疫反应,高剂量与Prevnar 20相匹配或超过20种共享血清型,并且在11个新型病毒中表现优于它. Vaxcyte's Phase 1/2 trial of VAX-31, a 31-valent pneumococcal vaccine, showed strong immune responses in adults 50 and older, with the high dose matching or exceeding Prevnar 20 for 20 shared serotypes and outperforming it for 11 new ones. 疫苗耐受性良好,副作用轻微且没有严重的不良反应. The vaccine was well-tolerated, with mild side effects and no serious adverse events. 它满足了所有31种血清型的免疫性目标,可能比目前疫苗提供更广泛的防治肺炎和侵袭性疾病. It met immunogenicity goals for all 31 serotypes, potentially offering broader protection against pneumonia and invasive disease than current vaccines. 高剂量药物目前正在第三期试验中,预计结果将在2026年底发布. The high dose is now in a Phase 3 trial, with results expected in late 2026.